Sensei Biotherapeutics (SNSE) AI Stock Analysis

• Market Cap: $40.06M
• Dividend Yield: N/A
• Average Volume (3M): 38.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: N/A
• EPS Growth: 9.63%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.79
• Shares Outstanding: 1,340,281
• 10 Day Avg. Volume: 109,584
• 30 Day Avg. Volume: 38,927
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.66
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: -6.85
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.59
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -15.05
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $34.00 ▲(197.72% Upside)
• Action: Reiterated Date: 03/31/26
• Date: Action: Reiterated 03/31/26

The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and a shrinking equity/asset base despite modest leverage). Technicals are mixed but somewhat supportive longer-term, while valuation remains challenging due to negative earnings. Corporate events provide some offset via added capital and pipeline expansion, tempered by meaningful dilution and control structure changes.

Positive Factors

Pipeline expansion (Faeth acquisition)

The stock-for-stock acquisition of Faeth and addition of PIKTOR meaningfully broaden Sensei’s oncology pipeline and shifts the company from a single-program profile to a multi-asset development platform. That diversification improves long-term R&D optionality and de-risks program-level binary outcomes across 2+ clinical programs.

Negative Factors

Pre-revenue biotech profile

Sensei remains a pre-revenue clinical-stage biotech dependent on external capital rather than internal cash generation. Sustained lack of commercial revenue means long-term viability hinges on successful clinical outcomes or continued financings, which amplifies execution and financing risk over the next several quarters.

Sensei Biotherapeutics Business Overview & Revenue Model

Company Description

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is ...

Read more

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is ...

How the Company Makes Money

null...

Sensei Biotherapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-551.00K	-571.00K	-1.81M	-685.00K
EBITDA	-20.91M	-29.52M	-33.39M	-46.56M	-35.44M
Net Income	-21.09M	-30.16M	-34.10M	-48.59M	-36.79M
Balance Sheet
Total Assets	22.90M	45.36M	74.37M	118.38M	153.22M
Cash, Cash Equivalents and Short-Term Investments	21.18M	41.34M	65.76M	107.12M	147.62M
Total Debt	1.51M	3.85M	6.21M	8.03M	2.35M
Total Liabilities	4.31M	6.97M	9.48M	14.97M	6.71M
Stockholders Equity	18.59M	38.39M	64.89M	103.41M	146.51M
Cash Flow
Free Cash Flow	-20.47M	-24.82M	-32.20M	-39.35M	-32.28M
Operating Cash Flow	-20.45M	-24.67M	-32.02M	-39.03M	-30.26M
Investing Cash Flow	19.77M	22.44M	38.41M	49.95M	-143.12M
Financing Cash Flow	-645.00K	-787.00K	-11.17M	-287.00K	163.94M

Sensei Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Neutral. The current price of 11.42 is below the 20-day moving average (MA) of 30.38, below the 50-day MA of 25.37, and below the 200-day MA of 13.23, indicating a neutral trend. The MACD of 1.16 indicates Positive momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 55.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SNSE.

Sensei Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCP	48 Neutral	$17.23M	-1.14	-94.94%	―	―	49.10%
BOLT	47 Neutral	$9.43M	-0.31	-97.58%	―	-46.88%	34.83%
SNSE	46 Neutral	$40.06M	-0.71	-80.00%	―	―	9.63%
BRTX	44 Neutral	$6.13M	―	-420.31%	―	1.70%	-111.67%
CLRB	43 Neutral	$11.70M	-0.59	-248.91%	―	―	79.31%

Sensei Biotherapeutics Corporate Events